One-year clinical outcome in patients with acute coronary syndrome treated with concomitant use of clopidogrel and proton pump inhibitors: Results from a regional cohort study

Journal of Cardiovascular Medicine

Volumn 13, Issue 12, 2012, Pages 783-789

  Ortolani, Paolo ^a   Marino, Massimiliano ^b   Marzocchi, Antonio ^a   De Palma, Rossana ^b   Branzi, Angelo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Regional Health Agency of Emilia Romagna   (Italy)

Author keywords

acute coronary syndrome; clopidogrel; proton pump inhibitors

Indexed keywords

CLOPIDOGREL; PROTON PUMP INHIBITOR;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; COHORT ANALYSIS; DRUG USE; FEMALE; FOLLOW UP; HEART MUSCLE REVASCULARIZATION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRESCRIPTION; RETROSPECTIVE STUDY;

ACUTE CORONARY SYNDROME; AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; DRUG INTERACTIONS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; ITALY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT READMISSION; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84870398677     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0b013e3283416b6b     Document Type: Article

References (25)

1. Ng FH, Wong SY, Chang CM, Chen WH, Kng C, Lanas AI, Wong BC. High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease. Aliment Pharmacol Ther 2003; 18:443-449.
2. Gilard M, Arnaud B, Le Gal G, Abgrall JF, Boschat J. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost 2006; 4:2508-2509.
3. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51:256-260.
4. Zuern CS, Geisler T, Lutilsky N, Winter S, Schwab M, Gawaz M. Effect of comedication with proton pump inhibitors (PPIs) on postinterventional residual platelet aggregation in patients undergoing coronary stenting treated by dual antiplatelet therapy. Thromb Res 2010; 125:51-54.
5. Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009; 101:714-719.
6. Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, Rumsfeld JS. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301:937-944.
7. Rassen JA, Choudhry NK, Avorn J, Schneeweiss S. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation 2009; 120:2322-2329.
8. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. Can Med Assoc J 2009; 180:713-718.
9. European Medicines Agency. Public statement on possible interaction between clopidogrel and proton-pump inhibitors. http://www.emea.europa.eu/ humandocs/PDFs/EPAR/Plavix/32895609en.pdf (accessed 12, March 2010)
10. Food and Drug Administration. Follow-up to the January 26 2009, early communication about an ongoing safety review of clopidogrel bisulfate (marketed as Plavix) and omeprazole (marketed as Prilosec and Prilosec OTC). http://www.fda.gov/Drugs/drugSafety/ postmarketDrugSafetyInformationforPatientsandProviders/ drugSafetyInformationforHeathcareProfessionals/ucm190784.htm (accessed 12 March 2010).
11. ATC/DDD Index. WHO collaborating centre for drug statistics methodology. 2006. Available at: http://www.whocc.no/atcddd (accessed 11 October 2007).
12. Ortolani P, Balducelli M, Marzaroli P, et al. Two-year clinical outcomes with drug-eluting stents for diabetic patients with de novo coronary lesions: results from a real-world multicenter registry. Circulation 2008; 117:923-930.
13. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007; 116:e148-e304.
14. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008; 52:1502-1517.
15. Savi P, Combalbert J, Gaich C, Rouchon MC, Maffrand JP, Berger Y, Herbert JM. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost 1994; 72:313-317.
16. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109:3171-3175.
17. Barragan P, Bouvier JL, Roquebert PO, et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilatorstimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003; 59:295-302.
18. Gurbel PA, Bliden KP, Samara W, Yoho JA, Hayes K, Fissha MZ, Tantry US. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 2005; 46:1827-1832.
19. Kwok CS, Loke YK. Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther 2010; 31:810-823.
20. Gaglia MA, Torguson R, Hanna N, et al. Relation of proton pump inhibitor use after percutaneous intervention with drug-eluting stents to outcomes. Am J Cardiol 2010; 105:833-838.
21. Li XQ, Andersson TB, Ahlstrom M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004; 32:821-827.
22. Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 2008; 48:475-484.
23. Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F, et al. Evaluating nonrandomised intervention studies. Health Technol Assess 2003; 7:iii-x, 1-173.
24. O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a protonpump inhibitor: an analysis of two randomised trials. Lancet 2009; 374:989-997.
25. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353:487-497.